ArticleScientific reports2026
Facile and cost-effective synthesis and characterization of hormone stabilized biocompatible gold nanoparticles for biomedical applications.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metal nanoparticles possess unique characteristic features suitable for biomedical and other biological applications such as antimicrobial activity to drug delivery. Non-toxic, biocompatible nanoparticles are essential for these applications. Many of previously described methods applied heat or boiling and toxic chemicals like SDS, beta mercaptoethanol, EDTA, sodium citrate for nanoparticles synthesis. The present research emphasizes the synthesis of the gold nanoparticles using a non-toxic reducing and stabilizing agent sodium thyroxine through a facile, cost effective, and eco-friendly method. The formation of gold nanoparticles was confirmed in the UV-visible spectrophotometer with a SPR peak at 522 nm. The synthesized gold nanoparticles were spherical shape and the particles size were found to be < 15 nm in HR-TEM instrumental analysis. Further, physicochemical characterization of the nanoparticles was analyzed by DLS, zeta potential, XRD, and FT-IR. In-vitro hemolytic assay and ESR estimation results revealed that the synthesized gold nanoparticles were more hemocompatible with human RBCs up to 500 µg/mL. Additionally, Vero and A549 cell lines were used to determine the nanoparticles biocompatibility using in-vitro MTT assay, wound healing assay, cell morphology analysis, and DNA fragmentation study. The in-vivo toxicity of the synthesized gold nanoparticles was analyzed by Hydra magnipapillata that result exhibited the biocompatibility of nanoparticles upto 600 µg/mL. Further, the biocompatibility of nanoparticles was confirmed by the morphological studies, feeding behavior, hydra regeneration study, and apoptosis analysis. Therefore, this gold nanoparticle can be utilized for various biomedical applications like drug delivery, gene delivery, photothermal therapy, biosensing, antimicrobial activity and bio-imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.